keyword
MENU ▼
Read by QxMD icon Read
search

Ivabradine

keyword
https://www.readbyqxmd.com/read/28205056/analyzing-health-related-quality-of-life-data-to-estimate-parameters-for-cost-effectiveness-models-an-example-using-longitudinal-eq-5d-data-from-the-shift-randomized-controlled-trial
#1
Alison Griffiths, Noman Paracha, Andrew Davies, Neil Branscombe, Martin R Cowie, Mark Sculpher
INTRODUCTION: The aim of this article is to discuss methods used to analyze health-related quality of life (HRQoL) data from randomized controlled trials (RCTs) for decision analytic models. The analysis presented in this paper was used to provide HRQoL data for the ivabradine health technology assessment (HTA) submission in chronic heart failure. METHODS: We have used a large, longitudinal EuroQol five-dimension questionnaire (EQ-5D) dataset from the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT) (clinicaltrials...
February 15, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28195070/effect-of-ivabradine-captopril-and-melatonin-on-the-behaviour-of-rats-in-l-nitro-arginine-methyl-ester-induced-hypertension
#2
S Aziriova, K Repova, K Krajcirovicova, T Baka, S Zorad, V Mojto, P Slavkovsky, J Hodosy, M Adamcova, L Paulis, F Simko
Cardiovascular diseases including hypertension are often associated with behavioural alterations. The aim of this study was to show, whether ivabradine, the blocker of If-channel in sinoatrial node, is able to modify the behaviour of rats in L-nitro-arginine methyl ester (L-NAME)-induced hypertension and to compare the effect of ivabradine with captopril and melatonin. 12-week-old male Wistar rats were divided into the following groups: controls, ivabradine (10 mg/kg/24 h), L-NAME (40 mg/kg/24 h), L-NAME + ivabradine, L-NAME + captopril (100 mg/kg/24 h), L-NAME + melatonin (10 mg/kg/24 h)...
December 2016: Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society
https://www.readbyqxmd.com/read/28185709/heart-failure-guidelines-what-s-new
#3
REVIEW
Lampros Papadimitriou, Carine E Hamo, Javed Butler
Heart Failure is a global epidemic, affecting approximately 5 million adults in the U.S.A. The cornerstone of contemporary pharmacological therapy targets the over activated renin-angiotensin-aldosterone and sympathetic autonomic systems. The 2016 focused pharmacologic update on the current Heart Failure Guidelines introduces the use of two newly approved regimens valsartan/sacubitril and ivabradine. Over the last two decades, guideline directed medical therapy has accomplished significant improvement in survival rates among heart failure patients; however these novel compounds were reported to exert additional mortality and morbidity benefits, in heart failure subpopulations with reduced ejection fraction...
January 11, 2017: Trends in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28177679/reduced-expression-of-hcn-channels-in-sinoatrial-node-of-streptozotocin-induced-diabetic-rats
#4
Xin Huang, Nier Zhong, Hong Zhang, Aiqun Ma, Zuyi Yuan, Ning Guo
Diabetes mellitus (DM) is associated with an electrical remodeling of the heart, increasing risk of arrhythmias. However, knowledge of electrical remodeling in sinoatrial node (SAN) by DM is limited. We investigated the expression of HCN channel isoforms, HCN1-HCN4, in SAN from streptozotocin (STZ)-induced diabetic rats and the age-matched controls. We found that the STZ-induced diabetic rats have a lower intrinsic heart rate, a lengthened sinoatrial conduction time and rate-corrected maximal sinoatrial node recovery time in vivo as well as a longer cycle length (CL) in vitro as compared with the control...
December 23, 2016: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/28115808/the-effects-of-ivabradine-on-left-ventricular-synchronization-and-tei-index-in-patients-with-systolic-heart-failure
#5
Fatma Hizal Erdem, Serkan Ozturk, Selçuk Öztürk, Alim Erdem, Selim Ayhan, Mustafa Öztürk, İbrahim Dönmez, Davut Baltacı, Mehmet Yazıcı
BACKGROUND: The aim of our study was to evaluate in stable outpatients with systolic heart failure (HF) the 3 months effect of ivabradine on LV synchronization and Tei index in stable outpatients with systolic HF. METHODS: We evaluated prospectively 40 (30 males, 10 females) patients with HF. All patients were evaluated before and after treatment by transthoracic M mode, two dimensional (2D), pulsed-wave (PW), continuous wave (CW), color flow and tissue Doppler imaging (TDI) and tissue synchronization imaging (TSI)...
January 2017: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/27984253/does-heart-rate-really-matter-to-patients-with-heart-failure
#6
Robert J H Miller, Jonathan G Howlett
PURPOSE OF REVIEW: Measurement of heart rate (HR) and rhythm is used to identify patients at increased risk of disease progression, guide selection of treatments and gauge response to therapy. RECENT FINDINGS: Lowering HR with a pure HR lowering agent (ivabradine) in heart failure with reduced ejection fraction (HFrEF) and sinus rate more than 70 beats/min despite beta blockade has been shown to improve outcomes. Additionally, coadministration of ivabradine and beta blockade may enhance symptoms and HR control...
March 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/27982270/elevated-heart-rate-is-associated-with-cardiac-denervation-in-patients-with-heart-failure-a-123-iodine-mibg-myocardial-scintigraphy-study
#7
Aline Sterque Villacorta, Humberto Villacorta, Jenne Serrão de Souza, José Antônio Caldas Teixeira, Maria Clara S S S Muradas, Christiane Rodrigues Alves, Bernardo Campanário Precht, Pilar Porto, Letícia Ubaldo, Cláudio Tinoco Mesquita, Antônio Cláudio Lucas da Nóbrega
Background: In the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT), heart rate (HR) reduction with ivabradine was associated with improved survival and reduced hospitalizations in patients with heart failure (HF). The mechanisms by which elevated HR increases mortality are not fully understood. Objective: To assess the relationship of baseline HR with clinical, neurohormonal and cardiac sympathetic activity in patients with chronic HF and elevated HR...
November 2016: Arquivos Brasileiros de Cardiologia
https://www.readbyqxmd.com/read/27972043/systematic-review-of-cost-effectiveness-analysis-of-ivabradine-in-heart-failure
#8
M Dehghani, M Varmaghani, F Sharifi
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27899939/beta-blocker-use-and-risk-of-symptomatic-bradyarrhythmias-a-hospital-based-case-control-study
#9
Hou Tee Lu, Jiyen Kam, Rusli Bin Nordin, Surinder Kaur Khelae, Jing Mein Wang, Chun Ngok Choy, Chuey Yan Lee
OBJECTIVE: To investigate the risk factors of symptomatic bradyarrhythmias in relation to β-blockers use. METHODS: A hospital-based case-control study [228 patients: 108 with symptomatic bradyarrhythmias (cases) and 120 controls] was conducted in Sultanah Aminah Hospital, Malaysia between January 2011 and January 2014. RESULTS: The mean age was 61.1 ± 13.3 years with a majority of men (68.9%). Cases were likely than control to be older, hypertensive, lower body mass index and concomitant use of rate-controlling drugs (such as digoxin, verapamil, diltiazem, ivabradine or amiodarone)...
September 2016: Journal of Geriatric Cardiology: JGC
https://www.readbyqxmd.com/read/27895488/advances-in-the-management-of-heart-failure-the-role-of-ivabradine
#10
REVIEW
Ursula Müller-Werdan, Georg Stöckl, Karl Werdan
A high resting heart rate (≥70-75 b.p.m.) is a risk factor for patients with heart failure (HF) with reduced ejection fraction (EF), probably in the sense of accelerated atherosclerosis, with an increased morbidity and mortality. Beta-blockers not only reduce heart rate but also have negative inotropic and blood pressure-lowering effects, and therefore, in many patients, they cannot be given in the recommended dose. Ivabradine specifically inhibits the pacemaker current (funny current, If) of the sinoatrial node cells, resulting in therapeutic heart rate lowering without any negative inotropic and blood pressure-lowering effect...
2016: Vascular Health and Risk Management
https://www.readbyqxmd.com/read/27880009/antianginal-efficacy-of-ivabradine-metoprolol-combination-in-patients-with-stable-angina
#11
John Zarifis, Manolis Kallistratos, Apostolos Katsivas
Medical treatment is the main clinical strategy for controlling patients with chronic stable angina and improving their quality of life (QoL). Ivabradine treatment on top of metoprolol decreases angina symptoms and improves QoL in patients with stable angina and coronary artery disease (CAD). This is a post hoc analysis (636 CAD patients given ivabradine/metoprolol free combination) of a prospective, noninterventional study that included 2403 patients with CAD and stable angina. Data were recorded at baseline at 1 and 4 months after inclusion...
December 2016: Clinical Cardiology
https://www.readbyqxmd.com/read/27867524/varying-effects-of-recommended-treatments-for-heart-failure-with-reduced-ejection-fraction-meta-analysis-of-randomized-controlled-trials-in-the-esc-and-accf-aha-guidelines
#12
REVIEW
Marius Mark Thomsen, Christian Lewinter, Lars Køber
The aim of this paper is to evaluate the treatment effects of recommended drugs and devices on key clinical outcomes for patients with heart failure with reduced ejection fraction (HFREF). Randomized controlled trials (RCTs) listed in the 2012 HF guideline from the European Society of Cardiology as well as the 2013 HF guideline from the American College of Cardiology Foundation and American Heart Association were evaluated for use in the meta-analysis. RCTs written in English evaluating recommended drugs and devices for the treatment of patients with HFREF were included...
December 2016: ESC Heart Failure
https://www.readbyqxmd.com/read/27861199/heart-rate-reduction-with-adjusted-dose-ivabradine-in-patients-undergoing-coronary-computed-tomographic-angiography-a-randomized-trial
#13
Blaž Kacijan, Zala Novak, Borut Jug, Maja Dolenc Novak, Matjaž Vrtovec, Barbara Gužič Salobir
OBJECTIVE: Our prospective, randomized, open-label study assessed the efficacy of a heart rate-lowering, adjusted-dose protocol with ivabradine prior to coronary computed tomographic angiography (CCTA). METHODS: Patients undergoing CCTA were randomized to 7 days of adjusted-dose ivabradine or standard care (ie, no additional medication). Heart rate and β-blocker and antianxiety medication use on the day of the CCTA were recorded. RESULTS: One hundred one patients were randomized (mean age, 60 [SD, 13] years; 66% women)...
November 17, 2016: Journal of Computer Assisted Tomography
https://www.readbyqxmd.com/read/27847478/the-protective-effects-of-ivabradine-in-preventing-progression-from-viral-myocarditis-to-dilated-cardiomyopathy
#14
Li Yue-Chun, Chen Guang-Yi, Ge Li-Sha, Xing Chao, Tian Xinqiao, Lin Cong, Dai Xiao-Ya, Yang Xiangjun
To study the beneficial effects of ivabradine in dilated cardiomyopathy (DCM) mice, which evolved from coxsackievirus B3-induced chronic viral myocarditis. Four-to-five-week-old male balb/c mice were inoculated intraperitoneally with coxsackievirus B3 (Strain Nancy) on days 1, 14, and 28. The day of the first virus inoculation was defined as day 1. Thirty-five days later, the surviving chronic viral myocarditis mice were divided randomly into two groups, a treatment group and an untreated group. Ivabradine was administered by gavage for 30 consecutive days in the treatment group, and the untreated group was administered normal saline...
2016: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/27846461/ivabradine-as-adjuvant-treatment-for-chronic-heart-failure
#15
Carolina C Mizzaci, Gustavo J M Porfírio, André T Vilela, José Cícero S Guillhen, Rachel Riera
BACKGROUND: Heart failure prevalence is rising throughout the world. Despite current multidrug therapy, heart failure is the cause of frequent hospitalizations and high mortality. OBJECTIVES: To assess the effectiveness and safety of ivabradine in chronic heart failure. METHODS: We searched the databases: the Cochrane Central Register of Controlled Trials CENTRAL (The Cochrane Library), MEDLINE, EMBASE, CINAHL, Conference Proceedings Citation Index - Science and Science Citation Index Expanded on Web of Science and LILACS...
January 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/27844147/acute-ivabradine-treatment-reduces-heart-rate-without-increasing-atrial-fibrillation-inducibility-irrespective-of-underlying-vagal-activity-in-dogs
#16
Kazunori Uemura, Masashi Inagaki, Can Zheng, Toru Kawada, Meihua Li, Masafumi Fukumitsu, Masaru Sugimachi
Ivabradine, a bradycardic agent, has been shown to stably reduce patient's heart rate (HR) in the setting of acute cardiac care. However, an association between atrial fibrillation (AF) risk and acute ivabradine treatment remains a controversial clinical issue, and has not been thoroughly investigated. Bradycardia and abnormal atrial refractoriness induced by ivabradine treatment may enhance vulnerability to AF induction, especially when vagal nerve is concurrently activated. We aimed to experimentally investigate the effects of acute ivabradine treatment with/without concurrent vagal activation on AF inducibility...
November 14, 2016: Heart and Vessels
https://www.readbyqxmd.com/read/27825166/the-effects-of-ivabradine-on-cardiac-function-after-myocardial-infarction-are-weaker-in-diabetic-rats
#17
Xue Cao, Zhijun Sun, Boya Zhang, Xueqi Li, Hongyuan Xia
BACKGROUND/AIMS: Plasma norepinephrine (NE) and brain natriuretic peptide (BNP, termed BNP-45 in rats) are considered as essential neurohormones indicating heart failure progression. The purposes of this study were to examine the effects of ivabradine (IBD) on cardiac function and plasma NE and BNP-45 after chronic ischemic heart failure (CHF) in non-diabetic rats and diabetic rats. We further determined if sympathetic NE uptake-1 (a major pathway to metabolize NE) mechanism is responsible for the role played by IBD...
2016: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/27822484/impact-of-ivabradine-on-inflammatory-markers-in-chronic-heart-failure
#18
Ilonka Rohm, Daniel Kretzschmar, Rudin Pistulli, Marcus Franz, P Christian Schulze, Christian Stumpf, Atilla Yilmaz
Background. Inflammation plays a crucial role in the progression of chronic heart failure (CHF). Ivabradine is known to reduce the morbidity and mortality of patients with CHF under certain conditions. Beyond the reduction of heart rate, only limited knowledge exists about potential anti-inflammatory effects of ivabradine that might contribute to its benefit in CHF. Thus, the present study aimed to investigate the effect of ivabradine on systemic inflammation. Methods. In the present study, 33 patients with CHF due to dilated, ischemic, and hypertensive cardiomyopathy were treated with ivabradine according to the guidelines of the European Society of Cardiology (ESC)...
2016: Journal of Immunology Research
https://www.readbyqxmd.com/read/27822397/management-of-stable-angina-with-ivabradine-as-safe-alternative-to-patients-with-myasthenia-gravis
#19
Giuliano Ohde Dalledone, Gustavo Lenci Marques, Renata Dal-Prá Ducci, Arnaldo Laffitte Stier Junior, Cláudia Suemi Kamoi Kay, Lineu Cesar Werneck, Paulo José Lorenzoni, Rosana Herminia Scola
Management of cardiac symptoms in myasthenia gravis (MG) patients can be challenging. The aim of this report is to describe the safe use of ivabradine for stable angina in MG patients. A 48 y.o. woman, with MG diagnosis, presented stable angina. Therapies choices were reduced considering concomitant disease as well as previous and unsuccessful cardiologic managements. Ivabradine showed unexpected results. The patient presented an improvement of neurological and cardiac symptoms, bringing ivabradine as one more therapeutic option to similar patients...
2016: Case Reports in Neurological Medicine
https://www.readbyqxmd.com/read/27821435/what-can-be-learned-from-recent-new-drug-applications-a-systematic-review-of-drug-interaction-data-for-drugs-approved-by-the-us-fda-in-2015
#20
Jingjing Yu, Zhu Zhou, Katie H Owens, Tasha K Ritchie, Isabelle Ragueneau-Majlessi
As a follow up to previous reviews, the aim of the present analysis was to systematically examine all drug metabolism, transport, pharmacokinetics (PK), and drug-drug interaction (DDI) data available in the 33 new drug applications (NDAs) approved by the Food and Drug Administration (FDA) in 2015, using the University of Washington Drug Interaction Database, and to highlight the significant findings. In vitro, a majority of the new molecular entities (NMEs) were found to be substrates or inhibitors/inducers of at least one drug metabolizing enzyme or transporter...
January 2017: Drug Metabolism and Disposition: the Biological Fate of Chemicals
keyword
keyword
6588
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"